Some Results of Photometric Measurements of Ionospheric Artificial Airglow at 557.7 and 630 nm Lines of Atomic Oxygen Caused by High-Frequency Radio Emission of the SURA Facility during Development of Sporadic E Layer

The results of analysis of the experimental data collected on 5 September 2021 on 557.7 and 630 nm artificial airglow of the ionosphere induced by powerful HF radio waves at the SURA facility are presented. For optical measurements, a photometric suite located directly next to the SURA facility was used. Fast variations in the atmospheric emission intensity at 557.7 nm, 630 nm, and 391.4 nm with a three-channel photometer and spatial–temporal variations in the 557.7 nm with a CCD camera were measured. An ionospherically reflected pump wave and the stimulated electromagnetic emission (SEE) were recorded. Background ionospheric conditions were registered with ionosonde. For the first time, an increase in the 557.7 nm emission intensity induced by the SURA facility radiation was found concurrently with a partial blocking ionosphere in the F-region and suppression HF-induced phenomena in the F-region (the 630 nm airglow increase and SEE generation, powerful radio wave anomalous absorption) during the sporadic E-layer (Es) development. Additionally, we managed to obtain images showing moving spots of the SURA-induced 557.7 nm emission increased intensity at the Es layer heights

Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology

Inter-patient molecular heterogeneity is the major declared driver of an expanding variety of anticancer drugs and personalizing their prescriptions. Here, we compared interpatient molecular heterogeneities of tumors and repertoires of drugs or their molecular targets currently in use in clinical oncology. We estimated molecular heterogeneity using genomic (whole exome sequencing) and transcriptomic (RNA sequencing) data for 4890 tumors taken from The Cancer Genome Atlas database. For thirteen major cancer types, we compared heterogeneities at the levels of mutations and gene expression with the repertoires of targeted therapeutics and their molecular targets accepted by the current guidelines in oncology. Totally, 85 drugs were investigated, collectively covering 82 individual molecular targets. For the first time, we showed that the repertoires of molecular targets of accepted drugs did not correlate with molecular heterogeneities of different cancer types. On the other hand, we found that the clinical recommendations for the available cancer drugs were strongly congruent with the gene expression but not gene mutation patterns. We detected the best match among the drugs usage recommendations and molecular patterns for the kidney, stomach, bladder, ovarian and endometrial cancers. In contrast, brain tumors, prostate and colorectal cancers showed the lowest match. These findings provide a theoretical basis for reconsidering usage of targeted therapeutics and intensifying drug repurposing efforts